In 2013, two companion papers indicated that 5-azacytidine and decitabine, which are well-known DNA methyltransferase inhibitors (DNMTi), induced differentiation of IDH1-mutant glioma cells and inhibited tumor growth in xenograft models [39,124]. This evidence concerns the gene IDH1 and central nervous system cancer.